R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl‐2 and bad phosphorylation
- 27 December 2006
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 211 (2) , 533-543
Abstract
Zoledronic acid (ZOL) has proved activity in bone metastases from prostate cancer through inhibition of mevalonate pathway and of prenylation of intracellular proteins. We have reported that ZOL synergizes with R115777 farnesyltransferase inhibitor (FTI, Zarnestra) in inducing apoptosis and growth inhibition on epidermoid cancer cells. Here, we have studied the effects of the combination of these agents in prostate adenocarcinoma models and, specifically, on androgen‐independent (PC3 and DU145) and ‐dependent (LNCaP) prostate cancer cell lines. We have found that ZOL and R115777 were synergistic in inducing both growth inhibition and apoptosis in prostate adenocarcinoma cells. These effects were paralleled by disruption of Ras→Erk and Akt survival pathways, consequent decreased phosphorylation of both mitochondrial bcl‐2 and bad proteins, and caspase activation. Finally, ZOL/R115777 combination induced cooperative effects also in vivo on tumor growth inhibition of prostate cancer xenografts in nude mice with a significant survival increase. These effects were paralleled by enhanced apoptosis and inactivation of both Erk and Akt. In conclusions, the combination between ZOL and FTI leads to enhanced anti‐tumor activity in human prostate adenocarcinoma cells likely through a more efficacious inhibition of ras‐dependent survival pathways and consequent bcl‐related proteins‐dependent apoptosis. J. Cell. Physiol. 211: 533–543, 2007.Keywords
This publication has 62 references indexed in Scilit:
- The farnesyl transferase inhibitor R115777 (Zarnestra®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa®) and PamidronateOncogene, 2004
- High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase InhibitorsJournal of Biological Chemistry, 2003
- Dual Protein Farnesyltransferase−Geranylgeranyltransferase-I Inhibitors as Potential Cancer Chemotherapeutic AgentsJournal of Medicinal Chemistry, 2003
- EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-α-mediated apoptosis in epidermoid cancer cellsCell Death & Differentiation, 2003
- Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibodyOncogene, 2001
- Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing BisphosphonatesBiochemical and Biophysical Research Communications, 1999
- Nitrogen-Containing Bisphosphonates Inhibit Isopentenyl Pyrophosphate Isomerase/Farnesyl Pyrophosphate Synthase Activity with Relative Potencies Corresponding to Their Antiresorptive Potenciesin Vitroandin VivoBiochemical and Biophysical Research Communications, 1999
- Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol DesignJNCI: Journal of the National Cancer Institute, 1994
- BisphosphonatesDrugs, 1991
- Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.BMJ, 1988